07/29/2020
SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, today announced two key executive appointments.
ABOUT US
Acquiring, developing and commercializing transformative medicines.
We are forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization. Our dedicated team is restless about ensuring our therapies ultimately reach patients with life-limiting diseases.
Founded in 2019, Engrail is supported by a long-term capital commitment from Nan Fung Life Sciences (NFLS).
OUR FOCUS
Significantly reducing overall disease burden.
In spite of the many treatments developed for the neurosciences, there continues to be immense disease burden on patients and significant economic impact.
Neuroscience has the potential to undergo a transformation. The brain’s complexities and molecular mechanisms — historically challenging to understand — are becoming clearer. Building on this new momentum and scientific understanding, we have a tremendous opportunity to develop and deliver transformative therapies that relieve patients’ overall disease burden.
OUR APPROACH
At Engrail, we apply a ‘science-first’ approach.
With our team’s thorough biological understanding of disease, we use rational therapeutic targeting to identify compounds with the greatest promise. We maximize our success by prioritizing acquisition of validated, clinical-stage compounds.
Our unique, flexible transaction model enables us to embrace a broad, open-minded way of thinking. By deploying thoughtful and creative development strategies, we can rapidly progress our therapies through development to commercialization.
Peter Bisgaard
Chairman
Karoly Nikolich, PhD
Board Member
Tony Ho, MD, PhD
Board Member
Vikram Sudarsan, PhD
President and CEO
Stephen Cunningham, MD
Chief Development Officer
INVESTORS
Vincent Cheung
Chairman, NFLS
Meng Gao
Managing Director, NFLS
NEWS
CAREERS
We are united by our core values.
Engrail is built on the foundation of a tight-knit group of entrepreneurs that embrace the right risks to achieve results. We foster integrity, diversity, transparency and clear communication. We are resilient and hold ourselves and each other accountable.
Are you interested in joining our ambitious and energetic team?
